Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Credit

<ul><li>DuPont de Nemours is a major specialty chemicals player formed after a series of acquisitions and divestitures.</li><li>Within the protection and water business, a mid-single digit growth in volume in shelter and water solutions is viewed.</li><li>The company is also on track with the acquisition of Laird Performance Materials for achieving $63 million in cost synergies.</li></ul>

DuPont de Nemours is a major specialty chemicals player formed after a series of acquisitions and divestitures.Within the protection and water business, a mid-single digit growth in volume in shelter and water solutions is viewed.The company is also on track with the acquisition of Laird Performance Materials for achieving $63 million in cost synergies.

DuPont de Nemours Inc.: Detailed Credit Analysis & Financial Strength Evaluation Report

Equity Bottom-Up

<ul><li>This is our first report on specialty chemicals giant, DuPont de Nemours.</li><li>The company has been in the corporate restructuring process since 2019, merging and divesting different business units.</li><li>Within the protection and water business, a mid-single digit growth in volume in shelter and water solutions is viewed.</li></ul>

This is our first report on specialty chemicals giant, DuPont de Nemours.The company has been in the corporate restructuring process since 2019, merging and divesting different business units.Within the protection and water business, a mid-single digit growth in volume in shelter and water solutions is viewed.

DuPont de Nemours Inc.: Initiation of Coverage – Restructuring Progress

Alpha-Centric ESG Research

Kyle Rudden

The Biden-Harris administration recently announced four "Day One" priorities, the first of which is their COVID-19 response plan. COVID-19 response is first, because it is a prerequisite to economic recovery, which is the second of their four "Day One" priorities.Several investment themes are inherent in Biden's COVID-19 plan, some more direct and obvious than others. This Insight overviews more significant themes and their most representative stocks, in three sections (the first two will be expanded on in separate upcoming reports):<ol>
<li>
COVID-19 Testing: Testing is the largest, most tangible, nearest-term investment opportunity created by Biden's plan. An estimated US$75-100 billion for testing could be windfall for certain stocks, but not all. Selectivity is key, and timing is critical (related to vaccine development).</li>
<li>
Vaccine Delivery: Biden's plan emphasises vaccine manufacturing and delivery, versus vaccine development (Trump had allocated <a href="https://www.hhs.gov/coronavirus/explaining-operation-warp-speed/index.html" target="_blank" rel="noopener">billions</a> to vaccine development companies). Some might go to big pharma companies for M&amp;D, but most should benefit other "cold chain" stocks.</li>
<li>
PPE Supply/Other: PPE manufacturing, of course, but that is largely old news. I will address it, but do so along with other more interesting collateral themes. For example, retail drugs chains, elder-care, medical technologies, and a few other related industries.</li>
</ol>

The Biden-Harris administration recently announced four "Day One" priorities, the first of which is their COVID-19 response plan. COVID-19 response is first, because it is a prerequisite to economic recovery, which is the second of their four "Day One" priorities.Several investment themes are inherent in Biden's COVID-19 plan, some more direct and obvious than others. This Insight overviews more significant themes and their most representative stocks, in three sections (the first two will be expanded on in separate upcoming reports):

COVID-19 Testing: Testing is the largest, most tangible, nearest-term investment opportunity created by Biden's plan. An estimated US$75-100 billion for testing could be windfall for certain stocks, but not all. Selectivity is key, and timing is critical (related to vaccine development).

Vaccine Delivery: Biden's plan emphasises vaccine manufacturing and delivery, versus vaccine development (Trump had allocated billions to vaccine development companies). Some might go to big pharma companies for M&amp;D, but most should benefit other "cold chain" stocks.

PPE Supply/Other: PPE manufacturing, of course, but that is largely old news. I will address it, but do so along with other more interesting collateral themes. For example, retail drugs chains, elder-care, medical technologies, and a few other related industries.


Biden COVID-19 Response Plan: Overview of Its Inherent Investment Themes

Technical Analyst, Vermilion Research

Joe Jasper

Technical Analyst

Technical and Quantitative Research

Vermilion Research

Vermilion’s objective is to deliver timely, actionable, and unique technical research to professional investors through the application of our various technical indicators.

Our research strategists seek to highlight securities which we believe are at major inflection points, based on our various technical and quantitative indicators, and offer asymmetric risk/return profiles. Our unique research methodology, centered on relative strength, enables our strategists to deliver superior investment recommendations.

Our process begins by organizing the universe of actively traded stocks into discrete sectors, then into industry groups. We then apply our technical and quantitative tools to identify developing price trends. Once attractive trends are identified within a selected sector or group, we screen for individual stocks which we believe offer the best risk/reward profile. We provide a historical perspective that often reveals, through our long-term charts, how price patterns often repeat themselves over time.

Technical Analysis

Due to uptrend violations for the Nasdaq 100, S&amp;P 500, and Russell 2000 we continue to believe near-term consolidation is likely -- potentially something similar to what the market experienced between June and early-July. In today’s report we highlight attractive Groups and stocks within Consumer Discretionary &amp; Materials: Retailers, Footwear, Retailers, Teenagers, Metals, Steel, Integrated, Non-U.S., and Chemicals, Diversified.

Due to uptrend violations for the Nasdaq 100, S&amp;P 500, and Russell 2000 we continue to believe near-term consolidation is likely -- potentially something similar to what the market experienced between June and early-July. In today’s report we highlight attractive Groups and stocks within Consumer Discretionary &amp; Materials: Retailers, Footwear, Retailers, Teenagers, Metals, Steel, Integrated, Non-U.S., and Chemicals, Diversified.

U. S. Equity Strategy: Bull-Bear Battle Continues

New and ongoing developments continue to support our bullish outlook. In the “new” column, we have bullish inflections in Treasury yields, the value vs. growth ratio, and broad commodities (Bloomberg Commodity index). These are classic signs that the economy is improving and is historically consistent with prior equity bull markets. Another new development is the market becoming increasingly overbought. As we outline in today's report, being “overbought” is far from a sell signal.  We also highlight attractive Groups and stocks within Energy and Materials: Large-, Mid-, and Small-Cap Domestic Oil &amp; Gas E&amp;P , Chemicals, Diversified, and Specialty Chemicals, Petro/Basic/Commodity.

New and ongoing developments continue to support our bullish outlook. In the “new” column, we have bullish inflections in Treasury yields, the value vs. growth ratio, and broad commodities (Bloomberg Commodity index). These are classic signs that the economy is improving and is historically consistent with prior equity bull markets. Another new development is the market becoming increasingly overbought. As we outline in today's report, being “overbought” is far from a sell signal.  We also highlight attractive Groups and stocks within Energy and Materials: Large-, Mid-, and Small-Cap Domestic Oil &amp; Gas E&amp;P , Chemicals, Diversified, and Specialty Chemicals, Petro/Basic/Commodity.

U.S. Equity Strategy: Value Overtaking Growth; Treasury Yields and Commodities Bottoming

United States

DuPont de Nemours, Inc. operates as a chemical company. The Company offers elastomeric photopolymer printing plates, structural and elastic adhesives, fluids, reinforcing composites, foams, coatings, rubber and elastomers, topical ingredients, food ingredients, animal nutrition, biomaterials, water purification technologies, and fibers.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

DuPont (DD US)

DuPont de Nemours Inc.: Detailed Credit Analysis & Financial Strength Evaluation Report

DuPont de Nemours is a major specialty chemicals player formed after a series of acquisitions and divestitures. Within the protection and water...

Baptista Research

DuPont de Nemours Inc.: Initiation of Coverage – Restructuring Progress

This is our first report on specialty chemicals giant, DuPont de Nemours. The company has been in the corporate restructuring process since 2019,...

Baptista Research

Biden COVID-19 Response Plan: Overview of Its Inherent Investment Themes

Biden's recently-announced COVID-19 response plan suggests a number of investment themes. This Insight overviews the more significant of those...

Kyle Rudden

U. S. Equity Strategy: Bull-Bear Battle Continues

Due to uptrend violations for the Nasdaq 100, S&P 500, and Russell 2000 we continue to believe near-term consolidation is likely -- potentially...

Vermilion Research

U.S. Equity Strategy: Value Overtaking Growth; Treasury Yields and Commodities Bottoming

New and ongoing developments continue to support our bullish outlook. In the “new” column, we have bullish inflections in Treasury yields, the...

Vermilion Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)